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Abstract
Long-term granulocyte-colony stimulating factor treatment has been shown to
be safe and effective in severe chronic neutropenia patients. However, data on
its use during pregnancy are limited. To address this issue, we analyzed all
pregnancies reported to the European branch of the Severe Chronic Neutropenia
International Registry since 1994. A total of 38 pregnancies in 21 women with
chronic neutropenia (16 pregnancies in 10 women with congenital, 10 in 6
women with cyclic, 12 in 5 women with idiopathic neutropenia) were reported.
Granulocyte-colony stimulating factor was administered throughout pregnancy
in 16 women and for at least one trimester in a further 5 women. No major
differences were seen between treated and untreated women with respect
to pregnancy outcome, newborn complications and infections. In addition, we
evaluated the genetic transmission of known or suspected genetic defects in 16
mothers having 22 newborns as well as in 8 men fathering 15 children. As a proof
of ...
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Introduction 
Severe chronic neutropenia is a heterogeneous group of
inherited and acquired rare disorders with a common hema-
tologic and clinical phenotype. It is characterized by peripher-
al blood absolute neutrophil counts below 0.5×109/L and early
onset of bacterial infections. 
Prior to the availability of recombinant human granulocyte-
colony stimulating factor (G-CSF), patients with severe chron-
ic neutropenia experienced frequent bacterial infections and
required multiple antibiotic courses. 
Data from the Severe Chronic Neutropenia International
Registry (SCNIR) have demonstrated that more than 90% of
all treated patients respond well to granulocyte-colony stimu-
lating factor with a sustained increase in absolute neutrophil
counts. Thus, patients are significantly less prone to bacterial
infections. As a consequence, life expectancy is prolonged and
our first patients have reached adulthood with the desire for
parenthood being an emerging issue.1-3 Patients and physi-
cians often ask about the benefits and safety of G-CSF treat-
ment during pregnancy and this led us to initiate this survey.
So far, only limited data are available on the risk of devel-
oping severe bacterial infections during pregnancy for women
suffering from severe chronic neutropenia (including congen-
ital, cyclic and idiopathic neutropenia) with or without G-CSF
treatment.
Because of the clinically distinguishable entities, in this
paper we discriminate between congenital and cyclic neu-
tropenia. While congenital neutropenia patients present with
persistent neutropenia, patients with cyclic neutropenia have
a cycling pattern of blood counts (neutrophils, platelets, retic-
ulocytes, monocytes). For practical reasons, we use the term
congenital neutropenia patients with non-cyclic congenital
neutropenias and the term cyclic neutropenia for patients
with cyclic hematopoiesis.
Current data on the molecular causes indicate that congen-
ital neutropenia is a genetic disorder with more than 10
underlying gene mutations described to date. However, in
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Long-term granulocyte-colony stimulating factor treatment has been shown to be safe and effective in severe
chronic neutropenia patients. However, data on its use during pregnancy are limited. To address this issue, we ana-
lyzed all pregnancies reported to the European branch of the Severe Chronic Neutropenia International Registry
since 1994. A total of 38 pregnancies in 21 women with chronic neutropenia (16 pregnancies in 10 women with
congenital, 10 in 6 women with cyclic, 12 in 5 women with idiopathic neutropenia) were reported. Granulocyte-
colony stimulating factor was administered throughout pregnancy in 16 women and for at least one trimester in a
further 5 women. No major differences were seen between treated and untreated women with respect to preg-
nancy outcome, newborn complications and infections. In addition, we evaluated the genetic transmission of
known or suspected genetic defects in 16 mothers having 22 newborns as well as in 8 men fathering 15 children.
As a proof of inheritance, neutropenia was passed on to the newborn in 58% from female and in 62% from male
patients with ELANEmutations, but also to some newborns from parents with unknown gene mutation. Based on
our results, granulocyte-colony stimulating factor therapy has been shown to be safe for mothers throughout preg-
nancies and for newborns without any signs of teratogenicity. With an increasing number of adult patients, genetic
counseling prior to conception and supportive care of mothers during pregnancy are crucial. The acceptance of
having affected children may reflect the high quality of life obtained due to this treatment. 
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ABSTRACT
approximately 30% of patients the genetic basis of con-
genital neutropenia is still unknown. Gene mutations
responsible for congenital neutropenia follow an autoso-
mal dominant, autosomal recessive or X-linked pattern of
inheritance depending on the type of mutation. Genetic
analyses in autosomal dominant and sporadic cases of
congenital neutropenia indicate that the majority of these
cases are attributable to mutations in the elastase 2
(ELANE) gene encoding neutrophil elastase. Thirty-two
percent of congenital (CN) and 80% of cyclic (CyN) neu-
tropenia patients harbor ELANEmutations (ELANE-CN vs.
ELANE-CyN), as reported by the European branch of the
Severe Chronic Neutropenia International Registry.
Although some mutations are related to both congenital
and cyclic neutropenia, the clinical phenotype and course
of disease differ significantly: ELANE-CN patients have
severe chronic neutropenia with a substantial risk of life-
threatening infections and a high risk for secondary
leukemias. They require higher G-CSF doses and may
develop G-CSF receptor (CSF3R/colony stimulating factor
3 receptor) mutations during life. In contrast, ELANE-CyN
patients respond to lower G-CSF doses and show the typ-
ical cycling of neutrophil counts throughout their life
without malignant transformation. Recessive inheritance
of congenital neutropenia is related to HAX1 gene muta-
tions (Kostmann syndrome patients) and a number of
other rare mutations that are mainly associated with
multi-organ involvement, for example, SBDS, G6PT
(SLC37A4), G6PC3 and p14 (LAMTOR2, MAPBPIP). In X-
linked subtypes, mutations in TAZ or WAS may be detect-
ed.4-11 The clinical status in newborns of mothers and
fathers with different genetic subtypes of congenital neu-
tropenia has not yet been reported.
Acquired neutropenias may be due to different reasons,
e.g. drug- or virus-induced or anti-granulocyte antibody-
related. Patients with acquired neutropenia for unknown
reasons are classified as idiopathic neutropenia.
In this study, we assessed the outcome of pregnancies
reported to the SCNIR in Europe since 1994 with regard to:
1) use of G-CSF and dosing during pregnancy; 
2) the impact of G-CSF treatment on pregnancy out-
come, maternal and newborn complications (e.g. infec-
tions during pregnancy and fetal teratogenicity) in all neu-
tropenia subtypes; 
3) the transmission of inherited neutropenia to new-
borns of mothers and fathers with different genetic neu-
tropenia subtypes.
Methods
Severe Chronic Neutropenia International Registry
Between November 1987 and August 2013, 601 patients with
different subtypes of severe chronic neutropenia were enrolled in
the Severe Chronic Neutropenia International Registry (SCNIR) in
Europe, based in Hannover, Germany. As a basis for our analysis,
out of the 601 patients, we identified 329 adults (female n=172;
male n=157) aged 18 years or over who were hence considered to
be of a reproductive age. The study was conducted in accordance
with the Declaration of Helsinki, under the auspices of the Human
Subjects Committee of the Medical School in Hannover,
Germany, and other participating institutions.
Patients were enrolled on referral from cooperating hematolo-
gists, pediatricians and other physicians in Europe using standard
enrollment procedures.1 At the time of enrollment, clinical and lab-
oratory information was reviewed by an expert clinician associat-
ed with the Severe Chronic Neutropenia International Registry
(SCNIR). Annual follow-up information was entered into a stan-
dardized database. Data on complications during pregnancy, preg-
nancy outcome and newborn complications have been gathered
by a survey using specific questionnaires. 
All G-CSF dose data (in micrograms per kilogram per day,
μg/kg/d) were obtained from the visit closest in time prior to preg-
nancy and were compared to the doses reported for each trimester
during pregnancy. 
Statistical analysis
We restricted our analysis to adult male and female patients (age
≥ 18 years), with reported father- or motherhood, respectively.
Each analysis was carried out using all subjects with available data.
We estimated the effect of G-CSF treatment during pregnancy by
comparing infectious events and maternal as well as fetal and
newborn complications in treated versus untreated women. We
compared the median G-CSF dose values in pregnant women by
trimester for each pregnancy versus the median G-CSF dose prior
to pregnancy according to neutropenia subtype using the
Wilcoxon rank sum test.12 The mean absolute neutrophil counts of
treated and untreated mothers were compared with an independ-
ent samples t-test.
The incidence of inherited neutropenia was calculated for each
genetic subtype based on the newborn absolute neutrophil count
and/or molecular genetic testing.
Results
Out of a total of 601 patients with different subtypes of
severe chronic neutropenia enrolled in the Severe Chronic
Neutropenia International Registry (SCNIR) in Europe,
329 patients aged 18 years and above (female n=172; male
n=157), considered to be of a reproductive age, were avail-
able for our study. Out of the female cohort (172 patients),
38 pregnancies were reported in 21 women (16 pregnan-
cies in 10 women with congenital neutropenia, 10 preg-
nancies in 6 women with cyclic neutropenia, 12 pregnan-
cies in 6 women with idiopathic neutropenia). In addition,
we collected data on 9 men fathering 16 children (8 chil-
dren of 5 fathers with congenital neutropenia, 7 children
of 3 fathers with cyclic neutropenia, one child of a father
with idiopathic neutropenia) (Figure 1). 
The median age of the mothers at delivery was 29 years
with a maximum age of 35 years. Hence, there were no
women with age-related high-risk pregnancies in our
analysis; this has been reported to be significantly
increased from age 35-40 years and even higher in women
aged over 40 years.13,14 
Use of G-CSF and dosing during pregnancy  
Data on the use of G-CSF were available in 35 of the 38
pregnancies. As shown in Figure 2, G-CSF was adminis-
tered in 21 pregnancies of 14 women (congenital neu-
tropenia: 13 pregnancies of 9 women; cyclic neutropenia:
5 pregnancies of 3 women; idiopathic neutropenia: 3 preg-
nancies of 2 women). Whereas the majority (81%) of
pregnant women diagnosed with congenital neutropenia
received G-CSF for at least one trimester, only 50% of the
women with cyclic neutropenia and 25% of women with
idiopathic neutropenia were treated. One mother with
cyclic neutropenia re-started G-CSF treatment for the last
seven weeks of her pregnancy after she had stopped treat-
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ment more than one year prior to pregnancy.
Three patients suffering from congenital neutropenia
did not receive G-CSF treatment for at least six months
prior to as well as during their pregnancy: One of these
women became pregnant prior to the availability of G-
CSF, one woman withdrew treatment despite history of
severe infections, and one woman stopped G-CSF for fam-
ily planning. One woman with cyclic neutropenia stopped
G-CSF treatment prior to pregnancy and developed a seri-
ous uterine infection followed by septic abortion (see
below).
Figure 3 shows the G-CSF doses during pregnancy for
each trimester. For this analysis, patients were divided
according to neutropenia subtype comparing the median
G-CSF dose prior to pregnancy (μg/kg/d) to the dose for
each trimester. Sixteen women received G-CSF through-
out their entire pregnancy. In all but one woman with a
stable long-term G-CSF dose G-CSF was continued during
the first trimester of the pregnancy independent of the
neutropenia subtype. Seven of the 12 women with con-
genital neutropenia continued G-CSF during the second
and third trimesters. Two women re-started treatment
only for the last trimester. Four women with cyclic neu-
tropenia received G-CSF treatment throughout their preg-
nancy and one only for the last trimester. One out of the 3
idiopathic neutropenia women discontinued G-CSF treat-
ment for the second and third trimesters.
In general, patients with congenital neutropenia require
higher median G-CSF doses than those with cyclic or idio-
pathic neutropenia due to the severity of the underlying
disease. This was also observed in our survey. Intriguingly,
in all pregnancies, the G-CSF dose used was lower than
the median dose prior to pregnancy indicating that
patients were monitored more carefully during pregnancy
and G-CSF was dosed as low as possible.
Absolute neutrophil counts were available in 18 of 21
women (13 treated and 5 untreated) of our cohort. A total
of 37 complete blood counts (CBC) were available in the
treated women showing a mean absolute neutrophil
count of 4572 and a median of 2600. In the 16 CBC of
untreated women the mean absolute neutrophil count
was 615 and the median was 475. The mean absolute neu-
trophil counts differ significantly between treated and
untreated women (P=<0.01).
Impact of G-CSF treatment on pregnancy outcome,
maternal and newborn complications (e.g. infections
during pregnancy and fetal teratogenicity) in all 
neutropenia subtypes 
The European branch of the SCNIR gathered all pre- and
postnatal complications concerning mothers and children
in correlation with G-CSF as shown in Tables 1 and 2.
Pregnancy outcome
Miscarriages, defined by the World Health Organization
(WHO) as the premature loss of a fetus up to 23 weeks of
pregnancy and weighing up to 500g,15 were reported in
both pregnancies with (2 of 21) and without (3 of 14) G-CSF
treatment: In G-CSF treated women with congenital neu-
tropenia 2 of 16 (age of mothers: 24 and 27 years) pregnan-
cies resulted in spontaneous miscarriages in weeks six and
11, respectively; none were reported in treated women suf-
fering from cyclic or idiopathic neutropenia. One untreated
28-year old woman with congenital and one untreated 31-
year old women with idiopathic neutropenia had one mis-
carriage each. One untreated 24-year old woman with
cyclic neutropenia had a septic abortion (Table 1).
Two stillbirths were reported in women with idiopathic
neutropenia. Unfortunately, no information on G-CSF
treatment during these pregnancies was available. One of
these women had 3 premature newborns in later pregnan-
cies. She delivered one child at 30 weeks of gestation and
premature twins (26 weeks of gestation) in another preg-
nancy. One of the twins died on Day four after birth for
unknown reasons. A second untreated woman with idio-
pathic neutropenia delivered her baby at 36 weeks of ges-
Pregnancy outcomes and G-CSF safety in SCN
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Table 1. Reported maternal and fetal complications.
Congenital Cyclic Idiopathic Total 
neutropenia neutropenia neutropenia events
Exposure to G-CSF yes no unk yes no unk yes no unk yes no
Total pregnancies (n) 13 3 0 5 5 0 3 6 3 21 9
Events (n) 5 3 0 3 3 0 0 1 2 8 7
Miscarriage 2 1 1 2 2
Stillbirth 2* 0 0
Septic abortion 1 0 1
Preeclampsia 1 1 1 1
Preeclampsia + HELLP 1 1 0
Gestational diabetes 1 0 1
Obstruction of the ureter due 1 1 0
to baby size
Post-partum infection due 
to incomplete placenta delivery 1 1 0
Upper respiratory tract infection 1 1 0
Carpal Tunnel Syndrome 1 0 1
Vaginal bleeding 1 0 1
Mastitis after delivery 1 1 0
* Two different mothers. The table shows all reported maternal complications by neutropenia subtype and G-CSF exposure during pregnancy. The types of event are listed in the first
column. The purple columns show events reported for congenital neutropenia mothers by G-CSF exposure (yes, no, unknown), the blue columns for cyclic neutropenia and the green
for idiopathic neutropenia. The last column summarizes the total number of events for all neutropenia subtypes. None of these complications have been reported to be associated
with G-CSF exposure. 
tation. One treated congenital neutropenia patient with
SBDS mutation gave birth to a 25+4 week old newborn.
In summary, a total of 5 preterm deliveries were reported
in our cohort (Table 1).
Maternal complications
Preeclampsia was the most frequent reported maternal
complication and occurred in treated as well as untreated
women (Table 1). In a 23-year old woman with
Shwachman-Diamond Syndrome, preeclampsia with
HELLP syndrome led to delivery of a 25+4 week prema-
ture healthy baby (see above). Other maternal complica-
tions were rare. Gestational diabetes was reported in a 26-
year old woman suffering from congenital neutropenia
who was not exposed to G-CSF. She also reported vaginal
bleeding in her second trimester. An obstruction of the
ureter due to the size of the baby was documented in one
treated 22-year old woman with congenital neutropenia.
One untreated 24-year old woman with cyclic neu-
tropenia who had stopped G-CSF treatment prior to preg-
nancy developed a serious uterine infection followed by a
septic abortion. Another 34-year old woman with cyclic
neutropenia required surgery for Carpal Tunnel Syndrome
which developed due to peripheral edema while she was
not receiving G-CSF. Therapy was re-started for the sur-
gery and maintained for the remaining seven weeks of
pregnancy; the pregnancy was later complicated by
preeclampsia and upper respiratory tract infection. 
After delivery, one treated 29-year old woman with con-
genital neutropenia developed mastitis and one treated 31-
year old woman with cyclic neutropenia experienced an
uterine infection due to incomplete placenta delivery. 
Newborn complications
Reported newborn complications included jaundice, hip
dysplasia, omphalitis and neonatal neutropenia (Table 2).
The transmission of inherited neutropenia to newborns
of mothers and fathers with different genetic 
neutropenia subtypes
To exclude or confirm neutropenia, CBC was taken in
25 of 41 newborns of mothers and fathers suffering from
congenital or cyclic neutropenia at birth and in 4 babies
later in life. Results are listed in Tables 3 and 4.  
Transmission of neutropenia was evaluated in new-
borns of 9 mothers and 7 fathers with known neutropenia
causing dominant ELANE mutation (congenital and cyclic
neutropenia) and in newborns of mothers and fathers
with unclassified congenital or cyclic neutropenia (6
women, one man) In 7 of 12 newborns neutropenia was
passed on from the mother (58%). In 8 of 13 newborns the
neutropenia was passed on from the fathers (62%). One
woman suffered from Shwachman-Diamond Syndrome
characterized by compound heterozygous SBDS muta-
tions without transmission to her baby, as expected. 
Interestingly, neutropenia was not only reported in chil-
dren of parents with ELANEmutations, but also in 6 of 11
newborns of parents with congenital (4 women, one man)
and cyclic neutropenia (2 women, no men) negative for
ELANE and HAX1 gene mutation or so far genetically not
C. Zeidler et al.
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Figure 1. Distribution of mother- and
fatherhood by neutropenia subtype.
Congenital neutropenia in purple;
cyclic neutropenia in blue and idio-
pathic neutropenia in green. The
first two columns of the figure show
the total number of pregnant
women (column 1) and the number
of reported pregnancies (column 2)
for those women. The third column
indicates the number of fathers and
the fourth column the number of
fatherhoods. 
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Table 2. Reported newborn complications. 
Congenital Cyclic Idiopathic Total
neutropenia neutropenia neutropenia events
Maternal exposure to G-CSF yes no unk yes no unk yes no unk yes no
Total live births (n) 11 2 0 5 4 0 3 5 1 19 11
Events (n) 7 4 0 2 3 0 1 4 0 10 11
Premature newborn 1 4 1 4
Jaundice 1 1
Left hip dysplasia (res. at 4 m.),
persistent ductus arteriosus 
(closed spontan. at 1 m.) 1 1
Omphalitis 1* 1
Neonatal neutropenia 6 2 2 3 8 5
*Newborn with neutropenia. 
tested. In one of these 11 newborns, the neutropenia sta-
tus is unknown. The occurrence of congenital or cyclic
neutropenia in these children indicates the transmission of
the neutropenia from their parents and suggests that these
parents suffer from another autosomal dominant genetic
defect.
Discussion
In the past, pregnancy has been a major concern for
patients with severe chronic neutropenia, considered to
increase the susceptibility to infections for women with
severe chronic neutropenia. For example, a 20-year old
Pregnancy outcomes and G-CSF safety in SCN
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Figure 2. G-CSF Treatment of mothers during pregnancy by
neutropenia subtype. The pie charts show the maternal G-
CSF exposure (G-CSF exposure, no G-CSF, unknown exposure)
by neutropenia subtype for each pregnancy: congenital neu-
tropenia in purple, cyclic neutropenia in blue and idiopathic
neutropenia in green.   
Table 3. Inheritance of neutropenia from affected mothers.
Mutations/genotypes Mothers (n) Newborns with Newborns Neutropenia status Miscarriages (n) Live births 
neutropenia w/o neutropenia unknown total
(n) (n) (n) (n)
ELANE-CN 5 4 2 1 6
Shwachman-Diamond Syndrome 1 1 1
ELANE-CyN 4 3 3 6
CN unclassified 4 4 2 2 6
CyN unclassified 2 2 1 1 3
Total mothers 16
Total pregnancy outcomes 13 9 0 4 22
Summary of the number of neutropenia-affected newborns (column 3), non-affected newborns (column 4) and newborns with unknown neutropenia status (column 5) of affected
mothers with different genetic subtypes of congenital or cyclic neutropenia (ELANE-CN: congenital neutropenia with ELANE mutations; ELANE-CyN: cyclic neutropenia with ELANE
mutations) as well as unclassified congenital and cyclic neutropenia.
Table 4. Inheritance of neutropenia from affected fathers.
Mutations/genotypes Fathers (n) Newborns Newborns Neutropenia status Newborns
with neutropenia w.o.  neutropenia unknown total
(n) (n) (n) (n)
ELANE-CN 4 4 1 1 6
Shwachman-Diamond Syndrome 0 0
ELANE-CyN 3 4 3 7
CN unclassified 1 1 1 2
CyN unclassified 0 0
Total fathers 8
Total fatherhood outcomes 8 5 2 15
Summary of the number of neutropenia-affected newborns (column 3), non-affected newborns (column 4) and newborns with unknown neutropenia status (column 5) of affected
fathers with different genetic subtypes of congenital or cyclic neutropenia (ELANE-CN: congenital neutropenia with ELANE mutations; ELANE-CyN: cyclic neutropenia with ELANE
mutations) as well as unclassified congenital and cyclic neutropenia. 
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woman was sterilized in the late 1980s prior to her mar-
riage to prevent infections in the post-partum period. In
1998, this woman became pregnant by in vitro fertilization
(IVF). She received G-CSF treatment in the last weeks of
her pregnancy and gave birth to a healthy baby without
developing any severe bacterial infections pre- and post-
partum.16 Interestingly, in reports on 2 women with cyclic
neutropenia by Katz17 and Pajor,18 the severity of neutrope-
nia-related symptoms decreased during pregnancy even
without G-CSF treatment, suggesting endogenous upregu-
lation of G-CSF and/or other hormones involved in
hematopoiesis. 
Since the late 1980s, granulocyte-colony stimulating fac-
tor (G-CSF) has been shown to be most effective in the
treatment of patients with severe chronic neutropenia by
increasing the absolute neutrophil counts and decreasing
the risk of bacterial infections significantly.3,19,20 In addition,
this treatment has prolonged the survival of patients suffer-
ing from severe chronic neutropenia, especially congenital
neutropenia subtypes, the most severe form that in the
past was associated with poor outcome. Under long-term
G-CSF treatment, even congenital neutropenia patients
have now reached adulthood and, therefore, the desire to
have children is now presenting itself.
There are no formal recommendations regarding the use
of G-CSF during pregnancy in women suffering from
severe chronic neutropenia. However, single case reports
documented that the use of G-CSF in pregnant women
was safe and well tolerated, although most of the women
received G-CSF only during the very last weeks of preg-
nancy16 or even when labor had already started in order to
prevent possible adverse effects on the fetus.21 One woman
with acquired chronic neutropenia and severe infectious
complications after delivery of her first baby, received G-
CSF prophylactically in the second pregnancy from week
37 onwards. Besides a good neutrophil response, she had
an uneventful delivery of her second child and no puerperal
complications.22 Previous data of the Severe Chronic
Neutropenia International Registry (SCNIR) from 2003
indicated that the proportion of live births in mothers
receiving G-CSF for a median period of two trimesters was
higher than in the untreated women.23 However, numbers
were too small to allow reliable recommendations on the
use of G-CSF during pregnancy to be developed. In addi-
tion, the 2003 study primarily included women with idio-
pathic neutropenia, whereas our cohort consists mainly of
women with severe congenital neutropenia. ELANEmuta-
tions were identified in 44% of these women documenting
the genetic background of neutropenia.
In general, patients with congenital neutropenia require
higher G-CSF doses than patients with cyclic or idiopathic
neutropenia and this correlates to the severity of the clini-
cal phenotype (e.g. impaired neutrophil production) and
the resulting risk of bacterial infections. In our cohort of 21
women, no bacterial infections were reported during preg-
nancy, regardless of the administration of G-CSF. In the
majority of documented pregnancies, women received G-
CSF for a minimum of one trimester. Reflecting the sever-
ity of the underlying neutropenia subtype, 81% of con-
genital compared to 50% of cyclic and 25% of idiopathic
neutropenia patients were treated. Fortunately, none of
our patients experienced severe bacterial infections. The
high proportion of treated women with the most severe
clinical phenotype (congenital neutropenia) corresponds
to the widely-reported high susceptibility of bacterial
infections and the documented risk of death from sepsis in
these patients.24 
Since G-CSF crosses the placental barrier, G-CSF treat-
ment during the late phase of pregnancy may also prevent
newborns with inherited neutropenia from perinatal
infections.25 This may be due to a neutrophil response in
the baby. 
Compared to the doses prior to pregnancy, the median
G-CSF doses administered during pregnancy were slightly
lower in our cohort. This finding may indicate that
women were monitored more carefully during pregnancy
in order to adjust the G-CSF dose to the minimal amount
needed to maintain the neutrophil count above 1x109/L.
Another explanation for sufficient absolute neutrophil
numbers under lower G-CSF doses might be the improve-
ment of neutropenia due to intrinsic increased levels of
steroid hormones and hematopoietic growth factors
including endogenous G-CSF during pregnancy that was
reported in cyclic neutropenia patients.26
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Figure 3. Median G-CSF dose prior and during pregnancy by neutropenia subtype. In the figure the median G-CSF doses (µg/kg/d) for each
neutropenia subtype (congenital neutropenia in purple; cyclic neutropenia in blue and idiopathic neutropenia in green) prior to pregnancy (first
column) are compared to the median G-CSF dose during pregnancy divided into the three trimesters (2-4 columns of each color). 
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Our evaluation demonstrates that G-CSF treatment
resulted in a significantly higher mean absolute neutrophil
count in treated compared to untreated women indicating
a better ability to fight bacterial infections. 
Thirty-one of the total 38 pregnancies resulted in live
births (82%). Our analysis showed a minor difference
between the proportion of miscarriages and septic abor-
tions in treated versus untreated mothers (2 vs. 3). Two
stillbirths were reported in one untreated mother and one
mother with unknown G-CSF exposure, both suffering
from idiopathic neutropenia. A significantly higher rate of
spontaneous miscarriages in untreated pregnant women
with severe chronic neutropenia had been previously
reported by Boxer et al. but could not be confirmed in our
study, where the difference in the number of miscarriages
was not significant.23
In our cohort, we documented 5 preterm deliveries in 3
different women corresponding to an incidence of 13.2%.
This incidence is significantly higher than the overall inci-
dence of premature newborns in Europe (2010: 6.2%).27
Advanced age as an additional risk factor for premature
delivery could be excluded in our cohort. The median age
of the mothers at birth was 29 years (max. 35 years). A sig-
nificantly increased risk of premature delivery has been
reported for women from the age of 35-40 years and is
even higher in women aged over 40 years.13,14 In the major-
ity of pregnancies resulting in preterm delivery, no G-CSF
was given. One preterm delivery was related to
preeclampsia in a woman with Shwachman-Diamond
syndrome. 
In summary, our evaluation demonstrates that the use of
G-CSF throughout pregnancy is safe and well tolerated.
No noticeable side effects were reported. Our data sup-
port the recommendation to continue G-CSF treatment in
women with different types of severe chronic neutropenia
throughout pregnancy to prevent major infections and
newborn complications. The recommendation is based on
the reported high risk for bacterial infections and septic
death in severe congenital neutropenia. The risk may be
lower for patients suffering from cyclic or idiopathic neu-
tropenia. However, since there is no better predictor for
this risk than the absolute neutrophil count, we would rec-
ommend offering G-CSF treatment to all patients with
absolute neutrophil counts below 0.5x109/L.
Compared to the number of motherhoods, the number
of reported fatherhoods is much lower. This may be due
to the low median age (23.9 years) of the male cohort. In
addition, fatherhoods may be under-reported in the fol-
low-up questionnaires. 
The high frequency of inherited neutropenias in new-
borns from affected congenital neutropenia mothers with
autosomal dominant gene mutations may result in a high-
er risk of puerperal complications. It remains unclear
whether G-CSF administration to the mother at the time
of delivery can alleviate infections in neutropenic new-
borns. 
In addition to the concern about the safety of G-CSF
during pregnancy, the question of transmission of the neu-
tropenia from parent to child has to be addressed. We,
therefore, analyzed the occurrence of neutropenia in new-
borns of congenital and cyclic neutropenia parents with
known or unknown germ-line gene mutations. Twenty-
five newborns were born to mothers or fathers (congenital
and cyclic neutropenia) with known ELANE mutation. Of
the 25 newborns, 15 were affected by neutropenia con-
firming the dominant inheritance of these mutations. This
proportion (60%) is higher than statistically expected for
dominant inheritance that may be due to the low number
of patients. Interestingly, the prevalence of neutropenia in
children from parents with unknown inherited gene muta-
tions indicates the existence of a yet unidentified gene
mutation.  
In general, the number of patients reaching adulthood
and developing a desire to have children is increasing, thus
the interest in pregnancy has become a crucial issue. Due
to the advances in genetic testing, the number of neu-
tropenia-causing gene mutations is still increasing. Genetic
counseling should be offered to all affected patients and
their families. Inheritance should also be considered in
patients with unclassified congenital neutropenia since
neutropenia may be passed on by either parent in an auto-
somal dominant pattern, as shown by our results. The
acceptance of having affected children may reflect the
high quality of life afforded by G-CSF treatment in affect-
ed parents. 
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